https://www.selleckchem.com/pr....oducts/elamipretide-
OBJECTIVES To investigate the effectiveness of low dose secondary/tertiary prophylaxis in severe Hemophilia A children and determine improvements in their daily life. METHODS Thirty Hemophilia A children (≤ 12 y) with factor VIII less then 2% and less than two joint bleeds without inhibitors, were given prophylaxis with recombinant Fc fusion long acting factor VIII (ELOCTATE) at 10 IU.kg-1 twice weekly for 1 y. Earlier, patients received on-demand FVIII for a minimum of six months. Outcome was measured in terms of annual bl
Like
Comment
Share
